HBA1C AN INACCURATE MEASURE OF GLYCEMIC CONTROL IN A FEMALE WITH HEREDITARY SPHEROCYTOSIS DESPITE NORMAL HEMOGLOBIN LEVELS
|
|
- Matthew Whitehead
- 6 years ago
- Views:
Transcription
1 Case Report HBA1C AN INACCURATE MEASURE OF GLYCEMIC CONTROL IN A FEMALE WITH HEREDITARY SPHEROCYTOSIS DESPITE NORMAL HEMOGLOBIN LEVELS Nora Alghothani, MD, MPH; Kathleen M. Dungan, MD, MPH ABSTRACT Objective: Earlier cases have documented a discrepancy between glycated hemoglobin A1c (HbA1C) levels and glycemic control in patients with diabetes and previously diagnosed hereditary spherocytosis (HS). However, this has not been reported in patients with normal hemoglobin (Hb) and red blood cell (RBC) indices. Methods: A 22-year-old Caucasian woman with type 1 diabetes since age 11 was referred to Endocrinology for persistent hyperglycemia. Results: The initial HbA1C was 5.1% with normal Hb, hematocrit, mean cell volume, mean corpuscular Hb concentration, and RBC distribution. Given self-reported hyperglycemia, fructosamine was checked and was elevated (358 mmol/l, normal [nl] mmol/l). Peripheral smear was normal. Professional retrospective continuous glucose monitoring (CGM) demonstrated marked hyperglycemic excursions, particularly in the evenings, with mean sensor glucose of 195 mg/dl ± 48, corresponding HbA1C of 5.5%, and fructosamine of 370 mmol/l. She later reported new diagnosis of HS in her mother, prompting workup for HS. A reticulocyte count was elevated at 5.4% (nl %), and an osmotic fragility test was supportive of HS with increased erythrocyte osmotic fragility. Conclusion: This case demonstrates a marked distortion of HbA1C in a patient with previously undiagnosed HS with normal Hb and other RBC indices. Given the relatively high frequency of mild HS, early testing should be considered in patients with an apparent discrepancy in HbA1C and meter readings, even in the absence of anemia. Alternate glycemic markers are necessary to monitor glucose control in affected patients. (AACE Clinical Case Rep. 2015;1:e194-e198) Abbreviations: CBC = complete blood count; CGM = continuous glucose monitoring; CSII = continuous subcutaneous insulin infusion; Hb = hemoglobin; HbA1C = glycated hemoglobin A1c; HS = hereditary spherocytosis; MDI = multiple dose injection; nl = normal; RBC = red blood cell INTRODUCTION Submitted for publication August 21, 2014 Accepted for publication September 29, 2014 From the Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University, Columbus, Ohio. Address correspondence to Dr. Kathleen M. Dungan; The Ohio State University Division of Endocrinology, Diabetes & Metabolism; 5th Floor McCampbell Hall; 1581 Dodd Drive; Columbus, OH Kathleen.dungan@osumc.edu DOI: /EP14394.CR To purchase reprints of this article, please visit: Copyright 2015 AACE. See accompanying article, p Diabetes is a costly illness affecting at least 8% of the United States population and is a leading cause of renal failure, limb amputations, and cardiovascular disease (1). The American Diabetes Association (ADA) recommends the use of hemoglobin A1c (HbA1c) testing to manage diabetes (2). However, the HbA1c has its limitations and may be misleading in patients with hemoglobinopathies or disturbances in erythropoiesis. HbA1c is reported to be falsely low in clinically relevant cases of hereditary spherocytosis (HS) given the shortened erythrocyte lifespan and reduced overall glucose uptake (3). However, mild HS with normal hemoglobin (Hb) levels accounts for 20 to 30% of cases (4) and is associated with a higher incidence of diabetes (5). We present here the first known case of a patient with This material is protected by US copyright law. To purchase commercial reprints of this article, visit For permission to reuse material, please visit e194 AACE CLINICAL CASE REPORTS Vol 1 No. 3 Summer 2015
2 HbA1c, Glycemic Control Discrepancy, AACE Clinical Case Rep. 2015;1(No. 3) e195 marked distortion of HbA1c and asymptomatic HS with normal Hb levels. CASE REPORT The patient was a 22-year-old Caucasian woman with type 1 diabetes diagnosed at age 11 who was referred to Endocrinology for persistent hyperglycemia. Her regimen consisted of insulin glargine 16 units twice daily and insulin lispro 8 units with meals. Her exam was normal without evidence for jaundice or hepatosplenomegaly. Her initial HbA1c was 5.1% (normal [nl] %) using the cation-exchange high performance liquid chromatography method, and routine chemistry and complete blood count (CBC) revealed normal creatinine (0.67 mg/dl, nl mg/dl), Hb (12.7 g/dl, nl g/dl), hematocrit (35.7%, nl 35-45%), mean cell volume (85.5 fl, nl fl), mean corpuscular Hb concentration (35.5 g/dl, nl g/dl), and red blood cell (RBC) distribution (14.7, nl ). Given self-reported hyperglycemia, fructosamine, which measures the glycosylation of serum proteins rather than Hb, was checked and found to be elevated (358 mmol/l, nl mmol/l). A peripheral smear was then obtained to assess for the presence of schistocytes or other RBC abnormalities that may falsely lower HbA1c, and found to be normal. One year after presentation, total bilirubin was slightly elevated at 1.7 mg/ dl (normal <1.5 mg/dl) with a normal direct bilirubin (0.1 mg/dl). A summary of serial laboratory values and concomitant treatment is shown in Table 1. The patient started subcutaneous continuous insulin infusion 2 years after presentation. At years 3 and 4 after presentation, professional retrospective continuous glucose monitoring (CGM) demonstrated marked hyperglycemic excursions, particularly in the evenings, with elevated mean sensor glucose and discordant HbA1c (Fig. 1 A-B). Four years after her initial presentation, she reported a new diagnosis of spherocytosis in her mother, which prompted a work-up for HS. A reticulocyte count was elevated at 5.4% (nl %) and an osmotic fragility test, which compares resistance of normal and pathologic red cells to various osmotic pressures, was supportive of HS with increased erythrocyte osmotic fragility due to spherocytosis (initial hemolysis began at 0.75% NaCl and completed at 0.50%, nl 0.45 and 0.30%). In year 5, she started realtime CGM in preparation for pregnancy, and glucose values dropped significantly (Table 1 and Fig. 1 C). DISCUSSION HS is a mostly autosomal dominant hemolytic anemia that is characterized by a RBC membrane defect that results in loss of membrane surface area and leads to abnormal osmotic fragility, increased destruction, and shortened lifespan of RBCs (6). The transformation of RBCs to a spherical shape is not always apparent on peripheral blood smear as was the case in our patient. The severity of HS may range from mild to life threatening. Although some patients may present with significant anemia, jaundice, and splenomegaly, others including our patient with mild HS, have no apparent anemia and are entirely asymptomatic. These patients are able to maintain normal Hb levels despite accelerated erythrocyte destruction due to a compensatory increase in erythropoietin-driven erythropoiesis (4) as reflected by higher reticulocyte counts and possibly elevated bilirubin. Date (Year after initial visit) 3/2007 (Baseline) 12/2008 (Year 1) 8/2009 (Year 2) 8/2010 (Year 3) 12/2011 (Year 4) 8/2012 (Year 5) Therapy Random Glucose (mg/dl) Fructosamine (mmol/l) Table 1 Patient Labs A1c ( %) H/H ( g/dl/35-45%) Total BR/Direct BR (<1.5 mg/dl/<0.3 mg/dl) MDI /35.7 NA MDI / /0.1 CSII / /0.2 CSII / /0.2 CSII /35.6 NA CSII + RTCGM /34.0 NA Abbreviations: BR = bilirubin; CSII = continuous subcutaneous insulin infusion; H/H = hemoglobin/hematocrit; MDI = multidose injection; RT-CGM = real-time continuous glucose monitoring.
3 e196 HbA1c, Glycemic Control Discrepancy, AACE Clinical Case Rep. 2015;1(No. 3) A B C Hour Glucose Sensor Overlay - Readings & Averages (mg/dl) Breakfast Lunch Dinner Glucose (mg/dl) AM 2 AM 4 AM 6 AM 8 AM 10 AM 12 PM 2 PM 4 PM 6 PM 8 PM 10 PM 12 AM Fig. 1. Continuous Glucose Monitoring Data. A, Retrospective CGM obtained during year 3 of follow-up on continuous subcutaneous insulin infusion with HbA1c 5.5% & Fructosamine 370 mmol/l, 195 ± 48 mg/dl. B, Retrospective CGM during year 4 of follow-up with concomitant HbA1c 5.2% and fructosamine 365 mmol/l (mean sensor glucose 228 ± 102 mg/dl. C, Real-time CGM during year 5 of follow-up with concomitant HbA1c of 4.0% and fructosamine of 289 mmol/l (mean sensor glucose 131 ± 60 mg/dl).
4 HbA1c, Glycemic Control Discrepancy, AACE Clinical Case Rep. 2015;1(No. 3) e197 The incidence of HS is thought to be much higher than previously reported, as mild cases are often not diagnosed. Kutter et al conclude an incidence of HS as high as 1 in 250 in a general European population (3), as well as a higher incidence of diabetes among patients with HS (5) when detected by baseline hematologic data rather than overt clinical symptoms, as hemolysis is often well compensated and tolerated. This conclusion impacts the use of HbA1c to diagnose and monitor diabetes as it may seriously underestimate the glucose load. The shortened RBC lifespan reduces exposure of Hb protein to circulating glucose and in turn leads to a falsely low level that underestimates glucose load (7). There have been previous case reports documenting inaccurate use of HbA1c in patients with HS leading to delayed diagnosis of diabetes (8) and failure to recognize severity of hyperglycemia in a patient with type 1 diabetes (9) as well as in a woman with type 2 diabetes whose poor glycemic control became apparent only after splenectomy (10). As all 3 patients reported had anemia, our case is the first to document such discrepancy between HbA1c and glycemic control in the absence of a low Hb level and abnormalities in other routine RBC indices. In 1 case, the Hb was transiently normal several years after diagnosis of HS, but other RBC indices were not reported (8). This case highlights the importance of additional testing, including an assessment of reticulocyte counts and bilirubin in patients with an apparent discrepancy in HbA1c and meter readings, even in the setting of normal CBC and peripheral blood smear. Additional evaluation for a clinically relevant discrepancy between HbA1c and glucose control should include a careful evaluation for Hb variants and disorders known to affect erythropoiesis. In many cases such as thyroid, renal, or liver disease, multiple factors may affect erythropoiesis in either direction, particularly during treatment. Therefore, the net discrepancy between HbA1c and glucose control may be small or difficult to predict. History should focus on personal or family history of disorders such as RBC disorders or recent transfusion, as well as medications that affect erythropoiesis. Exam should focus on assessment of physical features of associated diseases, such as hepatosplenomegaly. Laboratory evaluation should include a CBC, peripheral smear, Hb electrophoresis, reticulocyte count, TSH, and liver and renal function tests. Unfortunately, Hb variants may be clinically silent and may not be detected on routine laboratory testing (11). The American Association for Clinical Chemistry and ADA recommend reviewing manufacturer product instructions to determine specific interference factors and to guide selection in patients with a suspected discrepancy in HbA1c and glucose levels. The Boronate affinity chromotography assay methods are usually less affected by Hb variants. If HbA1c values remain inconsistent with the clinical presentation despite appropriate selection of an assay method, repeat testing using a method that is based on an analytical principle that is different from the initial measure is recommended. However, all methods are affected by abnormal erythropoiesis. A statement from the American Association of Clinical Endocrinologists/ American College of Endocrinology also cautions on the potential for spherocytosis to cause misleading HbA1c results in the diagnosis of diabetes (13). Furthermore, alternate glycemic markers may be necessary to monitor glycemic control in patients with HS or discrepant HbA1c and glucose. Fructosamine, which measures glycosylation of serum proteins (primarily albumin), and reflects mean glucose over about a 2-week duration given the shorter lifespan of albumin (14), was used in the case of our patient to more accurately reflect her diabetic control. However, there are limitations for its use, including falsely low readings in cases of hypoalbuminemia and interference by marked hyperbilirubinemia (>29 mg/dl) (15). The latter, however would only be clinically relevant in cases of marked hemolysis, and the patient would be expected to have other signs or symptoms. Other more recently developed markers may also be considered when available to monitor glycemic control in patients with medical conditions that distort HbA1c. Glycoalbumin was developed to counter the problems associated with fructosamine, as it is not affected by low-molecular weight substances such as bilirubin and may better indicate glycemic control in patients with advanced renal or liver failure (16,17). 1,5-Anhydroglucitol is an inverse marker of glycemic control that appears most useful to establish changes over very short intervals or to reflect postprandial glucose (17,18). Prospective studies with diverse populations and longer-term follow-up however are needed to better establish the utility of each of these markers in guiding therapy and preventing complications. CONCLUSION In conclusion, although often a harmless anomaly, clinically silent HS may be may delay the diagnosis and appropriate management of diabetes. A reticulocyte count should be included in the evaluation of patients with discordant HbA1c, even in the absence of anemia, and self-monitored blood glucose readings, alternative markers of glucose control, and use of CGM should be considered. Ultimately, only large-scale studies of patients with mild HS will allow us to understand its true impact on the diagnosis of diabetes and the role of alternate forms of glucose monitoring, particularly among patients with normal RBC indices. DISCLOSURE K.M.D. reports consulting activities with Eli Lilly and research support from Novo Nordisk and Merck. Dr. Alghothani has no multiplicity of interest to disclose.
5 e198 HbA1c, Glycemic Control Discrepancy, AACE Clinical Case Rep. 2015;1(No. 3) REFERENCES 1. Centers for Disease Control and Prevention National Diabetes Fact Sheet. Available at: gov/diabetes/pubs/factsheet11.htm. 2. American Diabetes Association. Standards of medical care in diabetes Diabetes Care. 2012;35:S11-S Kutter D, Thoma J. Hereditary spherocytosis and other hemolytic anomalies distort diabetic control by glycated hemoglobin. Clin Lab. 2006;52: Rocha S, Costa E, Catarino C, et al. Erythropoietin levels in the different clinical forms of hereditary spherocytosis. Br J Haematol. 2005;131: Kutter D. Hereditary spherocytosis is more frequent than expected: What to tell the patient? Bull Soc Sci Med Grand Duche Luxembg 2005: Bolton-Maggs PH, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol. 2012;156: Sacks DB. A1c vs. glucose testing: a comparison. Diabetes Care. 2011;34: Arnold JG, McGowan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1C levels. J Am Board Fam Med. 2007;20: Liew CF, Cheah JS. Hereditary spherocytosis, a pitfall in the assessment of glycaemic control. Singapore Med J. 2003;44: McCready F, Cundy T. Effects of splenectomy for hereditary spherocytosis on glycated haemoglobin in a woman with Type 2 diabetes. Diabet Med. 2009;26: Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3: Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57:e1-e Lin MJ, Hoke C, Ettinger B, Coyne RV. Technical performance evaluation of BM/Hitachi serum fructosamine assay. Clin Chem. 1996;42: Ambruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33: American Association of Clinical Endocrinologists Board of Directors; American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16: Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton) 2012;17: Dungan KM. Predicting outcomes and assessing control with alternate glycemic markers. Diabetes Technol Ther. 2012;14: Kim WJ, Park CY, Lee KB, et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care. 2012;35:
Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases
Clin Exp Nephrol (2015) 19:1179 1183 DOI 10.1007/s10157-015-1110-6 ORIGINAL ARTICLE Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other
More informationOne HbA1c Measurement Does Not Tell the Whole Story 5 Case Studies
One HbA1c Measurement Does Not Tell the Whole Story 5 Case Studies KRISTINA JACKSON BEHAN ABSTRACT Hemoglobin A1c is produced by an interaction between intracellular glucose and hemoglobin. This is a dynamic
More informationESM Table 2 Data extraction form and key data from included studies
ESM Table 2 Data extraction form and key data from included studies Author, year and title Behan, 2006 [21] Cessation of menstruation improves the correlation of FPG to hemoglobin A 1c in Caucasian women
More informationIntroduction and Approach to Anemia
2 nd lecture in Hematology by Dr.Alaa Fadhil Alwan Introduction and Approach to Anemia Anemia is defined clinically as a blood hemoglobin or hematocrit value that is below the appropriate reference range
More informationImproving the Accuracy of Hemoglobin A 1c. : Your Help Is Needed
Improving the Accuracy of Hemoglobin A 1c : Your Help Is Needed Kristina Jackson Behan, PhD, MT(ASCP) (Clinical Laboratory Sciences Program, University of West Florida, Pensacola, FL) DOI: 10.1309/RTVTWPYPTPA5YAGU
More informationHbA1c for the Diagnosis of Diabetes Mellitus. Sam Rowe, MBBS, MAEd, FRCPC Banff, Alberta November 25, 2011
HbA1c for the Diagnosis of Diabetes Mellitus Sam Rowe, MBBS, MAEd, FRCPC Banff, Alberta November 25, 2011 Disclosure last 2 years: Lilly HypoCCS Study Investigator Bristol-Myers Squibb - Speaker GlaxoSmith
More informationDiagnostic Approach to Patients with Anemia
J KMA Special Issue Diagnostic Approach to Patients with Anemia Seonyang Park, MD Department of Internal Medicine, Seoul National University College of Medicine E mail : seonpark@snu.ac.kr J Korean Med
More informationDr. Shiva Nazari Assistant Professor of Pediatric Oncologist & Hematologist Shahid Beheshti Medical Science University Mofid Children s Hospital
Dr. Shiva Nazari Assistant Professor of Pediatric Oncologist & Hematologist Shahid Beheshti Medical Science University Mofid Children s Hospital Reduction in the normal red cell survival (120 days) RBC
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationGlycated Hemoglobin/Glycated Protein
190.21 - Glycated Hemoglobin/Glycated Protein The management of diabetes mellitus requires regular determinations of blood glucose levels. Glycated hemoglobin/protein levels are used to assess long-term
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationManagement. (By the World Health Organization according to the magnitude of the enzyme deficiency and the severity of hemolysis)
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Management Definition: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited disorder caused by a genetic defect in the red blood cell
More informationOriginal Article. Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT
Original Article Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT Objective: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients 65 years
More information5/18/2010. History of 1,5 Anhydroglucitol (1,5 AG) Glucose Variability & Pattern Management: Way Beyond Logbooks. Normal Renal Glucose Handling
Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA Normal Renal Handling 180 g of glucose is filtered each day Virtually all glucose reabsorbed
More informationHeme Questions and Derivatives for the USMLE Step One Exam. Winter Storm Skylar Edition
Heme Questions and Derivatives for the USMLE Step One Exam Winter Storm Skylar Edition Howard J. Sachs, MD Howard@12DaysinMarch.com www.12daysinmarch.com Patient presents with RUQ pain. HIDA scan fails
More informationGlucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA
Glucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA 1 Normal Renal Glucose Handling 180 g of glucose is filtered each day Virtually all
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationCan glycated albumin assist in management of diabetes mellitus? Jasna Lenicek Krleza, PhD. Children s Hospital Zagreb, Croatia
Can glycated albumin assist in management of diabetes mellitus? Jasna Lenicek Krleza, PhD. Children s Hospital Zagreb, Croatia DIABETES MELLITUS COURSE SUBJECT 2001 2014 WHEN WE PREPARED PROGRAMME of THIS
More informationInsulin Pump Therapy for Type 2
9501172-011 Insulin Pump Therapy for Type 2 Objective To show the effectiveness of CSII for insulin-taking type 2 patients Key Points Tight glycemic control decreases risk of diabetes-related complications
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationHereditary Spherocytosis - A Rare Case Report
Case report Pravara Med Rev 2010; 2(4) Hereditary Spherocytosis - A Rare Case Report Nigwekar P*, Shrikhande D Y**, Niranjan B K, Shah N, Shukla T Abstract Eleven years old female child presented with
More informationApplications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington
Applications of Technologies to Your Patient Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington Disclosures Consultant: Abbott Diabetes Care, Roche
More informationUsefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care
C H A P T E R 41 Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care K Chaithanya Murthy, B Ramya, E Vidya, RM Anjana, V Mohan ABSTRACT Over the past decades, several newer technologies have
More informationThe role of glycated hemoglobin in the screening and diagnosis of renal posttransplantation diabetes
Federal University of Rio Grande do Sul Graduate Program in Endocrinology Brazil The role of glycated hemoglobin in the screening and diagnosis of renal posttransplantation diabetes Ana Laura Pimentel
More informationMoving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit
Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin
More informationCLINICAL AND LABORATORY PATTERNS OF HEREDITARY HAEMOLYTIC ANEMIAS IN CHILDREN FROM CENTRAL REGION OF ROMANIA
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 6 (55) No. 2-2013 CLINICAL AND LABORATORY PATTERNS OF HEREDITARY HAEMOLYTIC ANEMIAS IN CHILDREN FROM CENTRAL REGION OF
More informationEffects of thyroid hormone on glycated hemoglobin and glycated albumin levels in non-diabetic subjects with overt hypothyroidism
Diabetes Care Publish Ahead of Print, published online September 7, 2010 Effects of thyroid hormone on glycated hemoglobin and glycated albumin levels in non-diabetic subjects with overt hypothyroidism
More informationApproach to a pale child
Approach to a pale child Dr. Dafalla Ahmed Babiker Jazan university objectives Definition of anemia Classification and causes Important points in history and physical examination Investigations. Definition
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationSelecting a Hemoglobin A1C Point of Care Instrument. Objectives. Disclosure / Conflict of Interest 3/11/2015
Selecting a Hemoglobin A1C Point of Care Instrument Heather P. Whitley, PharmD, BCPS, CDE Associate Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Objectives Compare
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationPump and Sensor Data Interpretation. Irl B. Hirsch, MD University of Washington School of Medicine
Pump and Sensor Data Interpretation Irl B. Hirsch, MD University of Washington School of Medicine Dualities Research: Medtronic Diabetes Consulting: Abbott Diabetes Care, BD, Bigfoot, Roche Raise Your
More informationUnraveling Hemoglobinopathies with Capillary Electrophoresis
Session Number 2002 Unraveling Hemoglobinopathies with Capillary Electrophoresis David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu
More informationResearch Article. Advance Research Journal of Multi-Disciplinary Discoveries ISSN NO : IRON DEFICIENCY ANEMIA AND GLYCATED HEMOGLOBIN
IRON DEFICIENCY ANEMIA AND GLYCATED HEMOGLOBIN Research Article ISSN CODE: 2456-1045 (Online) (ICV-MDS/Impact Value): 2.31 (GIF) Impact Factor: 1.272 Copyright@IJF 2016 Journal Code: ARJMD/MDS/V-7.0/I-1/C-9/NOV-2016
More informationDiabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington
Diabetes Technology for the Endocrinologist, 2017 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia, Adocia,
More informationAbout the Project Education Play Community Games Publications News Help Home
About the Project Education Play Community Games Publications News Help Home About the Project Workbook Games Workshop poems Publications Events Writers Fructosamine to a1c conversion whst does dr Petre
More informationC. treatment with Desferal (deferoxamine mesylate USP, iron-chelating agent)
HEMOLYTIC ANEMIAS Single choice tests 1. Select the clinical manifestation that is not characteristic for the hemolytic crisis: A. decrease of the red blood cell count B. reticulocytosis C. jaundice D.
More informationSandra Božičević dipl. ing. med. biochem, Marijana Vučić Lovrenčić, PhD Vuk Vrhovac University Clinic, Zagreb, Croatia
16. PRE-ANALYTICAL, ANALYTICAL AND POST-ANALYTICAL FACTORS INFLU- ENCING SPECIFIC TESTS FOR DIAGNOSIS AND MONITORING OF DM-National network in quality assessment Prof. Dubravka Juretić, Ph.D. University
More informationADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values - New Treatment Guidelines Will Now be Needed
529638DSTXXX10.1177/1932296814529638Journal of Diabetes Science and TechnologyKlonoff research-article2014 Editorial ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values
More information39 year old F with sickle cell anemia presenting with pain crisis. Jess Hwang 11/8/12
39 year old F with sickle cell anemia presenting with pain crisis Jess Hwang 11/8/12 HPI Knee and back pain typical of usual crises Nausea and vomiting 2 days prior to admission Had previously been on
More informationHemoglobin A1c: Comparison of Pointe Scientific s 2-Part Direct Hemoglobin A1c with the Bio-Rad Variant II and the Tosoh G8
Hemoglobin A1c: Comparison of Pointe Scientific s 2-Part Direct Hemoglobin A1c with the Bio-Rad Variant II and the Tosoh G8 Joseph D. Artiss, Ph.D., FACB, Associate Professor of Pathology, Wayne State
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Alpha Thalassemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_thalassemia 9/2013 7/2017 7/2018 7/2017 Description
More informationReport of Beta Thalassemia in Newar Ethnicity
Report of Beta Thalassemia in Newar Ethnicity Rajendra Dev Bhatt 1*, Surendra Koju 2, Prabodh Risal 1 Affiliations: 1 Department of Clinical Biochemistry, Dhulikhel Hospital, Kathmandu University Hospital
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationHBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT
Basrah Journal Of Surgery Bas J Surg, September, 18, 2012 HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT MB,ChB, DA, FICMS, Lecturer in Anesthesiology, Department of Surgery, College of Medicine,
More informationWILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa
WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa Diabetes is clinically well defined by glycation of proteins 1. True 2. false So far, diabetes has been defined as a clinical condition
More informationResearch Article Hb A1c Separation by High Performance Liquid Chromatography in Hemoglobinopathies
Scientifica Volume 2016, Article ID 2698362, 4 pages http://dx.doi.org/10.1155/2016/2698362 Research Article Hb A1c Separation by High Performance Liquid Chromatography in Hemoglobinopathies Vani Chandrashekar
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationYear 2003 Paper two: Questions supplied by Tricia
QUESTION 65 A 36-year-old man presents in a post-ictal state after an observed generalised seizure. Full blood investigation shows: haemoglobin 0 g/l [128-175] mean corpuscular volume (MCV) 106 fl [80-7]
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationDelta Check Calculation Guide
Delta Check Calculation Guide National Technology 2017, All Rights Reserved By Senior Scientific Researcher, Asmaa Taher Table of Contents Definition... 2 Purpose... 2 Delta Check Research Studies... 2
More informationPediatrics. Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment. Definition. Epidemiology of Pyruvate Kinase Deficiency.
Pediatrics Pyruvate Kinase Deficiency (PKD) Symptoms and Treatment See online here Pyruvate kinase deficiency is an inherited metabolic disorder characterized by a deficiency in the enzyme "pyruvate kinase"
More informationUsing and Interpreting Diabetes Data. Irl B. Hirsch, MD University of Washington
Using and Interpreting Diabetes Data Irl B. Hirsch, MD University of Washington Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas,
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationHbA1c: what the GP needs to know
North West London Pathology HbA1c: what the GP needs to know Dr Shivani Misra MRCP, FRCPath, PhD Consultant in Metabolic Medicine & Chemical Pathology s.misra@nhs.net Twitter: @ShivaniM_KC Learning Objectives
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationWhen Accuracy Alone Is Not Sufficient: New Roles for Clinical Chemists
When Accuracy Alone Is Not Sufficient: New Roles for Clinical Chemists Gary L. Horowitz, MD Director, Clinical Chemistry, Beth Israel Deaconess Medical Center Associate Professor of Pathology, Harvard
More informationFlow Cytometric Osmotic Fragility Testing Does Reflect the Clinical Severity of Hereditary Spherocytosis
Cytometry Part B (Clinical Cytometry) 86B:436 443 (2014) Original Article Flow Cytometric Osmotic Fragility Testing Does Reflect the Clinical Severity of Hereditary Spherocytosis Ye Jee Shim 1 and Dong
More informationGLUCOSE MONITORING. How. When
GLUCOSE MONITORING Why Self-monitoring of blood glucose is the best way to see how your body handles food, activity, diabetes medication (pills and/or insulin), stress and illness. You can also see what
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationINTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED
INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED Rationale for Combining Iron & Vit-D Vit D deficiency and Iron deficiency Anaemia the two most menacing disorders - are inter-related
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationA prospective study of effect of iron deficiency anemia on HbA1c levels in nondiabetics
Original Research Article A prospective study of effect of iron deficiency anemia on HbA1c levels in nondiabetics CH Manoj Kumar 1, Geethika Nutakki 2* 1 Associate Professor, 2 Senior Resident Department
More informationSerum fructosamine and glycated haemoglobin
rchives of Disease in Childhood, 1986, 61, 113-117 Serum fructosamine and glycated haemoglobin measurements in diabetic control J HINDL, G M ROSTRON, S CLRK, ND J G1T Department of Biochemistry, Infirmary
More informationIt should be noted that in the initial stage, nearly all anemias are normocytic. The major primary causes of normocytic anemia are given in Table 1.
Normocytic Anemia JOHN R. BRILL, M.D., and DENNIS J. BAUMGARDNER, M.D., University of Wisconsin Medical School, Milwaukee Clinical Campus, Milwaukee, Wisconsin Am Fam Physician. 2000 Nov 15;62(10):2255
More informationInterference and Point-of-Care Testing Devices
Interference and Point-of-Care Testing Devices Nam K. Tran, PhD, HCLD, (ABB), FACB Associate Clinical Professor Director of Clinical Chemistry, Special Chemistry/Toxicology and POCT 1 Learning Objectives
More informationFigure 2.1: Glucose meter
CHAPTER TWO: MONITORING TECHNOLOGIES 2.1 Introduction Glucose monitoring is a method of self-testing glucose (blood sugar) levels for the management of diabetes. Traditionally, it involves pricking the
More informationGlycated albumin and glycated hemoglobin are differently influenced by endogenous insulin secretion in patients with type 2 diabetes mellitus
Diabetes Care Publish Ahead of Print, published online October 21, 2009 Endogenous insulin secretion and glycated proteins Glycated albumin and glycated hemoglobin are differently influenced by endogenous
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationReferences Required document for Laboratory Accreditation by the College of American Pathologists.
Subject Hemoglobin A1c Cobas c501 Index Number Lab-4004 Section Laboratory Subsection Chemistry Category Departmental Contact Benjamin Michel Last Revised 9/12/2016 References Required document for Laboratory
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationAnemia In the Insurance Applicant What do the numbers mean?
Anemia In the Insurance Applicant What do the numbers mean? Lisa Duckett, M.D. Vice President and Medical Director September 12, 2017 Goals of the presentation Develop a consistent way to analyze Complete
More informationSciTeMed Publishing Group
SciTeMed Publishing Group ORIGINAL ARTICLE Diabetes and Endocrinology Effect of Hemoglobin Levels and Sex on HbA1c Levels among Japanese Population Tomoko Nakagami, MD, PhD 1 *; Junko Oya, MD, PhD 1 ;
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationTopics of this lecture : RBC. Structural characteristics Hemoglobin Erythropoiesis Erythrocytes destruction
Topics of this lecture : RBC Structural characteristics Hemoglobin Erythropoiesis Erythrocytes destruction Structural characteristics Its small size and biconcave shape provides more surface area than
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationTypes of Anaemias and their Management. S. Moncrieffe, Pharm.D., MPH, Dip.Ed., RPh. PSJ CE Mandeville Hotel April 27, 2014
Types of Anaemias and their Management S. Moncrieffe, Pharm.D., MPH, Dip.Ed., RPh. PSJ CE Mandeville Hotel April 27, 2014 Objectives At the end of the presentations participants should be able to: 1. Define
More informationAnaemia due to a red blood cell membrane defect
Anaemia due to a red blood cell membrane defect BHS training course 2013 1 Red blood cell membrane defect Pathologies Clinical signs Diagnostic criteria Treatment (HS) 2 The pathologies Structural organisation
More information(anemia) ก hemoglobin concentration, hematocrit deviation 1 1 ก hemoglobin, hematocrit mean corpuscular volume (MCV) 2
ก ก. ก ก.. ก (anemia) ก hemoglobin concentration, hematocrit ก ก ก 2 Standard deviation 1 1 ก hemoglobin, hematocrit mean corpuscular volume (MCV) 2 Hemoglobin hematocrit MCV (g/dl) (%) (fl) ( ) 0.5-1.9
More informationAina Blood Monitoring System
Aina Blood Monitoring System Analytical Performance Summary The Aina Blood Monitoring System is a high quality and versatile multi-parameter diagnostic platform that is CE-marked and approved for sale
More informationNorbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article
524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More information